MedImmune Inc. <MEDI.O>, which earlier this month agreed to be bought by AstraZeneca Plc. <AZN.L> for more than $15 billion, reported on Monday that first-quarter profit more than tripled on increased sales of its respiratory drug Synagis.
Internet NewsShare and Enjoy:These icons link to social bookmarking sites where readers can share and discover new web pages.
Original post by Jessica Mintz, AP Business Writer and software by Elliott Back
